Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH)
PLOS One · 2025
DOI: 10.1371/journal.pone.0312893 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift PLOS One, 2025. Verfasst von Pedro Cahn und 15 weiteren Autor:innen. Beteiligte Einrichtung: Research Department, Fundación Huésped, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, HIV Infections. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundacion Huesped, CanSino Biologics Inc..
Abstract (Originalsprache)
Background
Despite higher risk of poorer outcomes and potential sub-optimal vaccine effectiveness, people living with HIV (PLWH) are underrepresented in SARS-CoV-2 vaccine trials. We evaluated the safety and immunogenicity of the Ad5-nCoV vaccine (CanSino Biologics Inc./The Beijing Institute of Biotechnology) in PLWH.
Methods
In this single arm, open-label Phase 2b trial, PLWH were enrolled in Argentina. Participants received two doses of Ad5-nCoV vaccine (intramuscular, dosage 5x10 10 viral particles) at days 0 and 56. The primary outcomes were safety as serious adverse events [SAE], solicited and unsolicited local and systemic adverse events, impact on HIV viral load and CD4 counts and immunogenicity measured by S-RBD IgG and pseudo-virus neutralizing antibodies (nAbs) up to 52 weeks (ClinicalTrials.gov:NCT05005156).
Findings
Between June 2021-January 2022, 140 PLWH received at least one dose of Ad5-nCoV vaccine. At baseline, the majority were on antiretroviral therapy (99.3%), virologically suppressed (93.6%), with a median (IQR) CD4-cell count:736 (531–946) cells/ul. At baseline, 38 (27%) participants were seropositive for S-RBD antibodies, and 40 (28%) for nAbs. There were no SAEs related to the vaccine. Solicited AE within 7 days after first and second dose occurred in 93 (69%) and 75 (60%) participants, mostly grade 1, included pain, drowsiness and headache. The incidence of unsolicited AE within 28 days of vaccination was 10.7%. There were no significant changes in plasma viral load, CD4 count, CD4/CD8 ratio and no new AIDS-defining illnesses were reported. There were significant increases in the geometric mean titers (GMT) of S-RBD and nAbs between baseline to week 52. Seroconversion rates 28 days after the first and second doses (day 84) were 80% and 94% for S-RBD, and 35% and 78% for nAbs.
Interpretation
The Ad5-nCoV vaccine was safe and induced an adequate immune response in virologically suppressed PLWH, maintaining high antibody titers at least during the first year post-vaccination. No significant changes were observed in plasma viral load, CD4 count and CD4/CD8 ratio
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Department, Fundación Huésped, Buenos Aires, Argentina.
- CanSino Biologics Inc, Tianjin, China.
- Hospital Juan A. Fernández, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
- FUNCEI, Ciudad de Buenos Aires, Buenos Aires, Argentina.
- Helios Salud, Ciudad de Buenos Aires, Buenos Aires, Argentina.
- Canadian Center for Vaccinology, Dalhousie University, Halifax, Canada.
ORCID-Profile: Pedro Cahn, Ruijie Wang
Förderung
- Fundacion Huesped
- CanSino Biologics Inc.
Zitieren
APA
Cahn, P., Barreto, L., Figueroa, M. I., Fink, V., Rolon, M. J., Lopardo, G., Cassetti, I., Ceschel, M., Patterson, P., Gambardella, L., Mernies, G., Nava, A., Gou, J., Wang, R., Zhu, T., & Halperin, S. A. (2025). Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH). PLOS One. https://doi.org/10.1371/journal.pone.0312893
Vancouver
Cahn P, Barreto L, Figueroa MI, Fink V, Rolon MJ, Lopardo G, et al. Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH). PLOS One. 2025. doi:10.1371/journal.pone.0312893
BibTeX
@article{Cahn2025,
author = {Cahn, Pedro and Barreto, Luis and Figueroa, Maria Ines and Fink, Valeria and Rolon, Maria Jose and Lopardo, Gustavo and Cassetti, Isabel and Ceschel, Mariela and Patterson, Patricia and Gambardella, Luciana and Mernies, Gissella and Nava, Agustin and Gou, Jinbo and Wang, Ruijie and Zhu, Tao and Halperin, Scott A},
title = {Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH)},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0312893}
}
EUVIMED